July 19, 2022 - Luye Pharma Group announced today that its investigational drug Rotigotine Extended-release Microspheres for Injection (LY03003) has met the expected endpoints in a phase III clinical ...
Shanghai, July 17, 2022 — Luye Pharma Group today announced that Lurbinectedin, an innovative anticancer drug, has been approved by the Hainan Medical Products Administration for urgent clinical use ...
The Phase III clinical trial results of Luye Pharma’s investigational drug LY03005, designated as a “Class 1 Chemical Drug” in China, were presented at the 2022 Annual Meeting of the American ...
Shanghai, China, April 12, 2022 — Luye Pharma Group announced today that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has accepted the Marketi...
Basel, Switzerland, March 31, 2022 – Luye Pharma Group (Luye Pharma) today announced that its subsidiary Luye Pharma Switzerland AG has entered into agreements with Exeltis Pharma México,...
Shanghai, China, March 21, 2022 – Luye Pharma Group announced today that its investigational drug, LY03005, has received approval from the Center for Drug Evaluation (CDE) at China's Nationa...
Hong Kong, China, March 4, 2022 — Luye Pharma Group today announced that it has filed a New Drug Application (NDA) in Hong Kong, China for Lurbinectedin, for the treatment of adult patients with meta...
Luye Pharma Group has announced a partnership between its wholly-owned subsidiary Yantai Luye Drugs Trading Co. Ltd. and Chengdu Biostar Pharmaceuticals Co., Ltd., a wholly-owned subsidiary of Beijing...
Luye Pharma Group announced on December 29 that the marketing authorization application for Goserelin Acetate Extended-release Microspheres for Injection (LY01005), an innovative formulation for the t...
Luye Pharma Group today released the encouraging top-line results from a Phase II clinical trial of its new antidepressant, Ansofaxine Hydrochloride Extended-Release Tablets (LY03005), at the 19th Nat...
TOP